Validation of the DAPT score: The saga continues

The optimal duration of dual antiplatelet therapy (DAPT) in patients treated with newer (non-first)generation stents remains uncertain. The landmark DAPT study revealed that extending DAPT duration beyond 12  months for an additional 18 months, as compared to 12 months of DAPT then subsequent aspirin use, resulted in 0.7% absolute reduction in very late stent thrombosis at the cost of a 0.9% absolute increase in moderate to severe bleeding [1]. Several randomized controlled trials have looked into this tradeoff between ischemic and bleeding events with extension of DAPT beyond a year [2–5].
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research